Notícias e Atividades da Arrowhead Pharmaceuticals
Presença
A Arrowhead Pharmaceuticals desenvolve medicamentos baseados em RNA para doenças graves. A empresa oferece pesquisa de medicamentos, desenvolvimento clínico e serviços de licenciamento para pacientes, profissionais de saúde e parceiros farmacêuticos.
Visão geral dos produtos e serviços da Arrowhead Pharmaceuticals:
- Medicamentos de RNA
- Descoberta de fármacos
- Desenvolvimento clínico
- Acordos de licenciamento
- Serviços de pesquisa
Receita: ~$27 million
Funcionários: 500
Sede: Pasadena, Estados Unidos
Arrowhead Pharmaceuticals é uma das ...
Arrowhead Pharmaceuticals é uma empresa listada sob o símbolo ARWR (US).
Fusão, aquisição e financiamento envolvendo Arrowhead Pharmaceuticals.
- Arrowhead Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 825 milhões de dólares. (publicado em 27 de novembro de 2024).
Executivos
Veja o organograma con seus 32 executivos principais
Biografias mais buscadas da Arrowhead Pharmaceuticals
- Christopher Anzalone, Chief Executive Officer and Chairman of the ...
- Hongbo Lu, Director
- Mauro Ferrari, Director
Criar um alerta
para seguir os movimentos de executivos da Arrowhead Pharmaceuticals.
Biotecnologia
Arrowhead Pharmaceuticals possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).
Popular M&A news in Biotecnologia
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado em 17 de julho de 2026).
- GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publicado em 15 de julho de 2026).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Arrowhead Pharmaceuticals, Inc.
- View more press releases Close
Redes sociais sobre Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Arrowhead Pharmaceuticals na LinkedIn, X (Twitter) e YouTube
